Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Pancreatic Beta-Cell Protection Market 2016 - Hot Targets & Pipeline Analysis Report - Research and Markets

Research and Markets
Posted on: 24 Aug 16

Research and Markets has announced the addition of the "Pancreatic Beta-Cell Protection - Hot Targets & Pipeline Analysis" report to their offering.

Pancreatic Beta-cell Protection Hot Targets & Pipeline Analysis gives comprehensive insight on the various drugs being developed for the treatment of Pancreatic Beta-cell protection. The report covers hot targets & molecules in research for beta-cell protection in both Type-1 diabetes & Type-2 diabetes disease progression.

This report enables Pharmaceutical /Biotech companies, Academic institutes, Individual researchers, Investors, Medical technology companies, Service providers and other associated stake holders to identify and analyze the available licensing/collaborative commercial opportunities in the Diabetes Drug market. The report also provides strategic insights on medicines that are likely to have an impact on beta-cell protection treatment space and potentially alter standards of care in the foreseeable future.

Therapies that are presently available for diabetes focus on reducing the disease symptoms, but there is a huge unmet need for therapies that can either slow or prevent the beta cell loss as there is a rapid loss of cells in type 1 diabetes and progressive loss in type 2 diabetes patients

Currently, researchers are focusing on novel therapeutic strategies aimed at restoring, or at least preventing further loss of beta cell mass in beta cell deficit type 1 and type 2 diabetes patients as endogenous secretion of insulin is advantageous over exogenous insulin such as direct effect on hepatic (liver) glucose metabolism. Hence, it provides a tremendous opportunity for upcoming therapies specific to Beta-cell loss such as MAbs, stem cell-based, gene therapies and RNA-based therapies. These modalities may provide beta-cell protection, regeneration, mass increase with additional benefits of weight loss, triglyceride lowering and kidney protection.

Key Topics Covered:

1 Report Description

2 Introduction-Pancreatic Beta Cell Protection

2.1 Diabetes Snapshot & Prevalence

3 Research Methodology

3.1 Sources

4 Hot Targets-Beta Cell Protection

5 Target Analysis

5.1 Top Targets

5.2 Top University/Company

6 Molecules - Beta Cell Protection

6.1 Beta Cell Protection Pipeline By Molecule Type

6.2 Small Molecules Segmentation By Phase

6.3 Large Molecules Segmentation By Phase

6.4 Beta Cell Protection Pipeline By Phases

6.5 Beta Cell Protection Pipeline By Companies

6.6 Beta Cell Protection - Molecules Vs Targets

7 Other Targets On Beta Cell Protection

8 Beta Cell Protection - Deals

9 Targets - Beta Cell Apoptosis

10 Other Targets On Beta Cell Apoptosis

For more information about this report visit

Related Topics: Endocrine and Metabolic Disorder Drugs

View source version on

Business Wire

Last updated on: 24/08/2016

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.